Plain-English translation of NCT05101551 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called combined with two standard chemotherapy drugs ( and ) in young people whose acute myeloid leukemia has come back after initial treatment or didn't respond to it. The study will first figure out which doses of all three drugs together are safe and work well, and then test whether the treatment is effective at higher doses. Researchers hope to find a new treatment option for children and young adults with this serious blood cancer.
Acute myeloid leukemia that comes back or doesn't respond to standard treatment is very difficult to treat, and young patients with relapsed disease have limited options. This medication works differently than standard chemotherapy, so combining it with drugs patients have already received might improve outcomes and help more patients survive.
You likely qualify if…
You likely don't qualify if…
You would take the new medication by mouth for 5 days at a time, while also receiving the two standard chemotherapy drugs through injection or infusion. Treatment cycles last 28 days, and you would typically receive 1 or 2 cycles, though some participants may receive extended treatment. You'll need regular blood tests and medical visits to monitor how the treatment is working and watch for side effects, and doctors will check your heart, liver, and kidney function throughout the study.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States